Does the media prefer ETON or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 2 mentions for Lantheus and 1 mentions for Eton Pharmaceuticals. Lantheus' average media sentiment score of 1.24 beat Eton Pharmaceuticals' score of 1.13 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ETON or BLTE?

In the previous week, Belite Bio had 19 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 20 mentions for Belite Bio and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.13 beat Belite Bio's score of 0.60 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ETON or LQDA?

In the previous week, Liquidia had 9 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 10 mentions for Liquidia and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.13 beat Liquidia's score of 0.76 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMRX or ETON?

In the previous week, Amneal Pharmaceuticals had 8 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 9 mentions for Amneal Pharmaceuticals and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.13 beat Amneal Pharmaceuticals' score of 0.30 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DFTX or ETON?

In the previous week, Definium Therapeutics had 9 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 10 mentions for Definium Therapeutics and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.13 beat Definium Therapeutics' score of 0.45 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eton Pharmaceuticals (ETON) Competitors

$58.83 -0.52 (-0.88%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$59.13 +0.30 (+0.52%)

As of 04:02 AM Eastern

Compare

ETON vs. LNTH, BLTE, LQDA, AMRX, and DFTX

Should you buy Eton Pharmaceuticals stock or one of its competitors? Eton Pharmaceuticals's main competitors and comparable companies include Lantheus (LNTH), Belite Bio (BLTE), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eton Pharmaceuticals compare to Lantheus?

Eton Pharmaceuticals (NASDAQ:ETON) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Lantheus has a net margin of 17.69% compared to Eton Pharmaceuticals' net margin of 12.02%. Eton Pharmaceuticals' return on equity of 40.13% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Lantheus	17.69%	28.10%	14.35%

Eton Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Eton Pharmaceuticals presently has a consensus price target of $67.50, suggesting a potential upside of 14.74%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.36%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has higher revenue and earnings than Eton Pharmaceuticals. Lantheus is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	21.03	-$4.60M	$0.38	154.82
Lantheus	$1.54B	4.26	$233.56M	$4.14	24.32

In the previous week, Lantheus had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 2 mentions for Lantheus and 1 mentions for Eton Pharmaceuticals. Lantheus' average media sentiment score of 1.24 beat Eton Pharmaceuticals' score of 1.13 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Eton Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Belite Bio?

Eton Pharmaceuticals (NASDAQ:ETON) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Belite Bio had 19 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 20 mentions for Belite Bio and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.13 beat Belite Bio's score of 0.60 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Eton Pharmaceuticals has a net margin of 12.02% compared to Belite Bio's net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Belite Bio	N/A	-11.84%	-11.62%

Eton Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	21.03	-$4.60M	$0.38	154.82
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eton Pharmaceuticals currently has a consensus target price of $67.50, indicating a potential upside of 14.74%. Belite Bio has a consensus target price of $218.73, indicating a potential upside of 19.42%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts plainly believe Belite Bio is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Eton Pharmaceuticals beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Liquidia?

Eton Pharmaceuticals (NASDAQ:ETON) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Eton Pharmaceuticals has higher earnings, but lower revenue than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	21.03	-$4.60M	$0.38	154.82
Liquidia	$158.32M	39.08	-$68.92M	$1.37	50.45

In the previous week, Liquidia had 9 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 10 mentions for Liquidia and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.13 beat Liquidia's score of 0.76 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Eton Pharmaceuticals' net margin of 12.02%. Liquidia's return on equity of 149.65% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Liquidia	30.74%	149.65%	36.30%

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eton Pharmaceuticals currently has a consensus price target of $67.50, suggesting a potential upside of 14.74%. Liquidia has a consensus price target of $98.08, suggesting a potential upside of 41.90%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Summary

Liquidia beats Eton Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Amneal Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Amneal Pharmaceuticals had 8 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 9 mentions for Amneal Pharmaceuticals and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.13 beat Amneal Pharmaceuticals' score of 0.30 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has a net margin of 12.02% compared to Amneal Pharmaceuticals' net margin of 5.05%. Eton Pharmaceuticals' return on equity of 40.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Amneal Pharmaceuticals currently has a consensus target price of $19.57, indicating a potential upside of 13.46%. Eton Pharmaceuticals has a consensus target price of $67.50, indicating a potential upside of 14.74%. Given Eton Pharmaceuticals' higher possible upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Amneal Pharmaceuticals has higher revenue and earnings than Eton Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.82	$72.06M	$0.49	35.20
Eton Pharmaceuticals	$79.95M	21.03	-$4.60M	$0.38	154.82

Summary

Amneal Pharmaceuticals beats Eton Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Eton Pharmaceuticals has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Eton Pharmaceuticals	$79.95M	21.03	-$4.60M	$0.38	154.82

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Definium Therapeutics presently has a consensus price target of $63.00, indicating a potential upside of 65.83%. Eton Pharmaceuticals has a consensus price target of $67.50, indicating a potential upside of 14.74%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Definium Therapeutics had 9 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 10 mentions for Definium Therapeutics and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.13 beat Definium Therapeutics' score of 0.45 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has a net margin of 12.02% compared to Definium Therapeutics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Summary

Eton Pharmaceuticals beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.70B	$12.51B	$7.22B	$12.88B
Dividend Yield	N/A	2.61%	2.55%	9.95%
P/E Ratio	154.82	794.76	271.77	25.29
Price / Sales	21.03	955.42	714.62	118.07
Price / Cash	11,449.49	91.31	77.55	52.32
Price / Book	60.03	10.61	10.51	6.26
Net Income	-$4.60M	$2.82B	$3.48B	$357.86M
7 Day Performance	-1.79%	-1.93%	-1.15%	-0.56%
1 Month Performance	34.71%	3.14%	2.03%	-1.04%
1 Year Performance	237.72%	5.72%	21.92%	11.31%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	3.6266 of 5 stars	$58.83 -0.9%	$67.50 +14.7%	+229.6%	$1.70B	$79.95M	154.82	20	Positive News
LNTH Lantheus	3.724 of 5 stars	$101.20 +0.2%	$108.11 +6.8%	+82.9%	$6.61B	$1.54B	24.45	1,193	Positive News
BLTE Belite Bio	3.0224 of 5 stars	$154.47 -0.8%	$205.80 +33.2%	+178.9%	$6.22B	N/A	N/A	10	Trending News Analyst Forecast Insider Trade
LQDA Liquidia	4.2453 of 5 stars	$68.61 +0.6%	$98.08 +43.0%	+148.6%	$6.15B	$158.32M	50.13	50
AMRX Amneal Pharmaceuticals	3.7428 of 5 stars	$17.74 +1.5%	$19.00 +7.1%	+74.4%	$5.65B	$3.02B	36.12	8,500	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. LNTH, BLTE, LQDA, AMRX, and DFTX

How does Eton Pharmaceuticals compare to Lantheus?

Summary

How does Eton Pharmaceuticals compare to Belite Bio?

Summary

How does Eton Pharmaceuticals compare to Liquidia?

Summary

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. LNTH, BLTE, LQDA, AMRX, and DFTX

How does Eton Pharmaceuticals compare to Lantheus?

Is ETON or LNTH more profitable?

Which has more risk and volatility, ETON or LNTH?

Do institutionals and insiders hold more shares of ETON or LNTH?

Do analysts prefer ETON or LNTH?

Which has higher valuation & earnings, ETON or LNTH?

Does the media prefer ETON or LNTH?

Summary

How does Eton Pharmaceuticals compare to Belite Bio?

Does the media prefer ETON or BLTE?

Which has more volatility and risk, ETON or BLTE?

Is ETON or BLTE more profitable?

Which has stronger earnings & valuation, ETON or BLTE?

Do institutionals and insiders believe in ETON or BLTE?

Do analysts recommend ETON or BLTE?

Summary

How does Eton Pharmaceuticals compare to Liquidia?

Which has preferable earnings & valuation, ETON or LQDA?

Does the media favor ETON or LQDA?

Which has more volatility & risk, ETON or LQDA?

Is ETON or LQDA more profitable?

Do institutionals & insiders hold more shares of ETON or LQDA?

Do analysts recommend ETON or LQDA?

Summary

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Which has more volatility & risk, AMRX or ETON?

Do institutionals & insiders believe in AMRX or ETON?

Does the media prefer AMRX or ETON?

Is AMRX or ETON more profitable?

Do analysts recommend AMRX or ETON?

Which has better earnings & valuation, AMRX or ETON?

Summary

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Which has better valuation and earnings, DFTX or ETON?

Do institutionals and insiders believe in DFTX or ETON?

Do analysts rate DFTX or ETON?

Does the media prefer DFTX or ETON?

Is DFTX or ETON more profitable?

Which has more risk & volatility, DFTX or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools